LFBC(SZ:002513)2022-12-08 02:06Group 1: Company Development Plans - The company plans to operate in both pharmaceutical and pesticide sectors, with potential for external acquisitions to expand these businesses [1] - The focus will be on light asset development in the pesticide sector, while the pharmaceutical sector will adapt based on actual conditions [1] Group 2: Acquisition Progress - The acquisition of Ark Pharmaceutical is in progress, with the issuance already approved but awaiting formal approval from the CSRC [1] - Ark Pharmaceutical has around 200 sales personnel and covers provincial channels [1] Group 3: Financial Performance - The main reason for the company's loss in 2015 was due to Ningxia Bluefeng, which incurred a loss of approximately 60 million due to environmental rectification halting production [3] - The main plant reported a profit of over 14 million in the first nine months of 2015, with expectations for improvement in Q4 [3] - The company anticipates that the pesticide and pharmaceutical sectors will perform well in 2016, with Ark Pharmaceutical expected to achieve a performance commitment of approximately 90 million [4]